Kynam Capital Management, LP Biocryst Pharmaceuticals Inc Transaction History
Kynam Capital Management, LP
- $1.22 Billion
- Q3 2024
A detailed history of Kynam Capital Management, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 9,085,368 shares of BCRX stock, worth $69.7 Million. This represents 5.66% of its overall portfolio holdings.
Number of Shares
9,085,368
Previous 8,826,710
2.93%
Holding current value
$69.7 Million
Previous $54.5 Million
26.58%
% of portfolio
5.66%
Previous 4.25%
Shares
9 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$156 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$153 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$91 Million1.36% of portfolio
-
State Street Corp Boston, MA8.85MShares$67.9 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$62.4 Million1.15% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.43B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...